Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Anika Therapeutics, Inc. (ANIK)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
$19.33-5.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.95 → 0.95 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ANIK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA margin between 5% and 10% | A primary condition in Anika Therapeutics, Inc.'s published investment case. The stated target is 5% to 10%. | Improving | Adjusted EBITDA margin falls below 5% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ANIK is a small-cap healthcare business with a growth-and-margin-improvement thesis, rather than a proven profitable compounder. The multi-year view is intact, but the recent signal has eased from favorable to mildly favorable, and the evidence base has medium confidence.
ANIK is valued at a substantial premium to peers, and the evidence labels that premium unjustified. The expectations gap is elevated, but the model has low confidence, so the exact market assumptions are uncertain.
Near term, recent execution is strong: second-quarter revenue rose from the first quarter, Commercial and OEM channels grew year over year, and adjusted EBITDA and its margin improved. Management has raised its 2026 margin guidance, while the business remains loss-making and elevated risk, including a history of a deep miss, tempers that progress.
Over the next few quarters, the thesis depends on continued channel growth and delivery against the raised margin guidance; reversing that guidance would also damage management credibility. Over the multi-year view, regulatory progress for Cingal and Hyalofast matters, while weaker job growth could pressure cyclical healthcare names and strong results from sector peers could support sector momentum.
The 1-3 year thesis remains intact on improving execution, but profitability, regulatory timing, and an expensive valuation remain key uncertainties. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Anika Therapeutics, Inc.'s published investment case. The stated target is >= $0.41 per share. |
| Improving |
| EPS falls below $0.41 in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
OEM Channel revenue between $61M and $64.5M | A supporting condition in Anika Therapeutics, Inc.'s published investment case. The stated target is $61M to $64.5M. | Intact | OEM Channel revenue falls below $61M in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Total revenue growth between 1% and 9% | A primary condition in Anika Therapeutics, Inc.'s published investment case. The stated target is 1% to 9% YoY growth. | Intact | Revenue growth falls below 1% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.46 → $0.95 · observed estimates
$0.13B → $0.13B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-07-25 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-07-26 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-07-27 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-07-28 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-07-29 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-07-30 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-07-31 | $0.46 | $126,580,000 | 1 / 2 |
| 2026-08-01 | $0.46 | $128,558,500 | 1 / 2 |
| 2026-08-02 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-03 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-04 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-05 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-06 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-07 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-08 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-09 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-10 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-11 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-12 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-13 | $0.95 | $128,558,500 | 1 / 2 |
| 2026-08-14 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-15 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-16 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-17 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-18 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-19 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-20 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-21 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-22 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-23 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-24 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-25 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-26 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-27 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-28 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-29 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-30 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-08-31 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-09-01 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-09-02 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-09-03 | $0.73 | $128,558,500 | 1 / 2 |
| 2026-09-04 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-05 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-06 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-07 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-08 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-09 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-10 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-11 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-12 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-13 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-14 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-15 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-16 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-17 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-18 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-19 | $0.73 | $128,558,500 | 1 / 1 |
| 2026-09-20 | $0.95 | $128,258,500 | 1 / 1 |
| 2026-09-21 | $0.95 | $128,258,500 | 1 / 1 |
| 2026-09-22 | $0.95 | $128,258,500 | 1 / 1 |
| 2026-09-23 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-09-24 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-09-25 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-09-26 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-09-27 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-09-28 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-09-29 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-09-30 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-01 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-02 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-03 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-04 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-05 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-06 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-07 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-08 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-09 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-10 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-11 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-12 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-13 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-14 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-15 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-16 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-17 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-18 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-19 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-20 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-21 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-22 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-23 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-24 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-25 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-26 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-27 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-28 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-29 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-30 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-10-31 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-11-01 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-11-02 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-11-03 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-11-04 | $0.95 | $128,258,500 | 1 / 2 |
| 2026-11-05 | $0.95 | $128,258,500 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.